
    
      The study consists of dose escalation and dose expansion, the mTPI-2 (Modified Toxicity
      Probability Interval) will be used for dose exploration. The preset dose of KN046 is 5 mg/kg
      Q3W and the preset dose of ningatinib is 10 mg (rapid titration), 20 mg QD, 30 mg QD, and 40
      mg QD.Dose expansion will be divided into two cohorts, cohort 1 will enroll subjects who have
      not received system therapy and cohort 2 will enroll subjects who have previously received at
      least first-line system therapy.
    
  